DGAP-News: BB Biotech AG / Key word(s): Annual Results/Dividend BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed 21.01.2022 / 07:00 The ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: ...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies, today ...

Technvaio forecast the global agricultural biotechnology market is expected to grow by USD 25.30 billion during 2021-2025. This marks a significant market slow down compared to the 2019 growth ...

Welcome back to the working world, friends, I hope that you survived the return to the desk in good stead and are both warm and healthy. The current boom in COVID cases is a huge bummer, but perhaps ...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today in ...

2021 saw a rush of biotechs heading for the public markets, including companies seeking an initial public offering before ever producing a shred of clinical evidence. And they paid for it. Biotech ...

The FDA approval of Biogen's Alzheimer's disease drug Aduhelm was the biggest surprise. Several COVID-19 vaccine stocks skyrocketed well beyond expectations. Relatively few mergers and acquisitions ...

The Nasdaq Biotechnology Index (NBI™) was launched on Nov. 1, 1993, when the biotech industry was still in its relative infancy and prone to heightened volatility. Ten years later, the index tracked ...

Despite the success of COVID vaccines and medicines, the biotech sector underperformed the broader market in 2021. The Medical-Biomedical and Genetics industry declined 21.6% in 2021 against the S&P ...

Evommune went public late last year and is taking on stiff competition in immunology with a recent mid-stage clinical win.

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...